Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)

NCT01994382 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01994382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01994382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell or T-Cell Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 30, 2013
Completion date
December 15, 2020
Enrollment
260 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive nhl (a nhl), b-cell non hodgkin lymphoma (nhl), chronic lymphocytic leukemia (cll) / small lymphocytic lymphoma (sll), follicular lymphoma (fl/indolent nhl), t-cell lymphoma (ptcl and ctcl)